---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009428"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:35:07.751700+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lipocine reports FY2025 net loss of $9.6M; cash $14.9M; PPD Phase 3 topline due April 2026

## Summary
- Net loss of $9.6M ($1.69/diluted) vs $8K net income in FY2024; revenue fell to $2.0M from $11.2M.
- Cash and equivalents $14.9M at Dec 31, 2025, increased to $24.7M post-ATM offering in Q1 2026.
- Phase 3 study of LPCN 1154 (PPD) completed last patient visit; topline data expected early April 2026.
- R&D expenses rose to $8.6M from $7.4M on higher clinical study costs; G&A down to $3.8M.
- Company plans 505(b)(2) NDA submission for LPCN 1154 in mid-2026 if Phase 3 successful.

## SEC filing metadata
- accession: 0001493152-26-009428
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226009428/0001493152-26-009428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226009428/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009428
- JSON: https://secwatch.observer/filing/0001493152-26-009428.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.